To visit the old Ventura website, click here.
Ventura Wealth Clients Login here
Refer and earnSupport
logosearch
Create Account
hamburger
home
breadcrumbStocks
breadcrumbNectar Lifesciences Ltd Share Price
breadcrumbResults

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on March 31, 2025Data in Crores of INR
Revenue
₹ 430.69-2.42% from last year
Operating profits
₹ -154.23-408.62% from last year
Net income
₹ -130.09-22037.44% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Net worth1069.251064.591087.911062.031136.131105.161058.661006.68954.08
Fixed assets642.71661.97723.10771.89784.85824.82852.36881.24905.58
Debt635.54753.83859.93903.41778.76903.45955.05878.11962.11
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating224.69133.6595.0121.38284.96239.2465.17198.76168.82
Investing -17.0351.7016.64-28.62-33.13-26.13-29.44-18.10-76.88
Financing -205.44-185.58-119.3811.49-251.87-201.09-39.60-204.12-88.68

Financial ratios

Profitability ratiosinfo2
ROA0.23%
ROE0.47%
ROCE6.54%
EPS0.22%
Net profit margin0.3%
Operating profit margin9.13%
Dividend per share
Operational ratiosinfo2
Quick ratio0.59%
Current ratio1.32%
Interest coverage1.19%
Assets turnover0.89%
Debt to equity0.59%
Valuation ratiosinfo2
P/E ratio
P/B ratio0.4%
Dividend yield
EV/EBITDA
Nectar Lifesciences (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. NLL has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. NLL is catapulting itself into Cephalosporin Formulations in a defining way by entering lucrative regulated markets like US & European Union.
personal

Grow your wealth with more research recommendations

+91